EXEL Exelixis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EXEL

Price (delayed)

$22.52

Market cap

$6.83B

P/E Ratio

34.65

Dividend/share

N/A

EPS

$0.65

Enterprise value

$6.75B

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work ...

Highlights
The company's EPS has surged by 132% QoQ and by 14% YoY
The company's net income has surged by 126% QoQ and by 14% YoY
EXEL's quick ratio is down by 33% year-on-year and by 13% since the previous quarter
The company's equity fell by 9% YoY and by 3.6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.exelixis.com
Peers: MRK BMY AMGN JNJ

Key stats

What are the main financial stats of EXEL
Market
Shares outstanding
303.19M
Market cap
$6.83B
Enterprise value
$6.75B
Valuations
Price to earnings (P/E)
34.65
Price to book (P/B)
3.09
Price to sales (P/S)
3.91
EV/EBIT
26.23
EV/EBITDA
21.64
EV/Sales
3.69
Earnings
Revenue
$1.83B
EBIT
$257.52M
EBITDA
$312.21M
Free cash flow
$292.86M
Per share
EPS
$0.65
Free cash flow per share
$0.92
Book value per share
$7.28
Revenue per share
$5.75
TBVPS
$9.05
Balance sheet
Total assets
$2.94B
Total liabilities
$678.45M
Debt
$189.94M
Equity
$2.26B
Working capital
$923.68M
Liquidity
Debt to equity
0.08
Current ratio
3.34
Quick ratio
3.13
Net debt/EBITDA
-0.23
Margins
EBITDA margin
17.1%
Gross margin
96%
Net margin
11.4%
Operating margin
9.3%
Efficiency
Return on assets
6.8%
Return on equity
8.6%
Return on invested capital
10.7%
Return on capital employed
10.1%
Return on sales
14.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXEL stock price

How has the Exelixis stock price performed over time
Intraday
0.13%
1 week
-1.27%
1 month
-4.05%
1 year
17.54%
YTD
-6.13%
QTD
-5.1%

Financial performance

How have Exelixis's revenue and profit performed over time
Revenue
$1.83B
Gross profit
$1.76B
Operating income
$170.89M
Net income
$207.77M
Gross margin
96%
Net margin
11.4%
The company's net income has surged by 126% QoQ and by 14% YoY
The net margin has soared by 119% from the previous quarter
EXEL's operating margin is down by 26% year-on-year
Exelixis's operating income has decreased by 15% YoY

Growth

What is Exelixis's growth rate over time

Valuation

What is Exelixis stock price valuation
EXEL P/E details
P/E
34.65
P/B
3.09
P/S
3.91
EV/EBIT
26.23
EV/EBITDA
21.64
EV/Sales
3.69
The company's EPS has surged by 132% QoQ and by 14% YoY
The P/E is 28% below the last 4 quarters average of 48.2 and 5% below the 5-year quarterly average of 36.6
EXEL's P/B is 10% above its last 4 quarters average of 2.8
The company's equity fell by 9% YoY and by 3.6% QoQ
EXEL's price to sales (P/S) is 23% lower than its 5-year quarterly average of 5.1
The revenue has grown by 14% YoY and by 3.1% from the previous quarter

Efficiency

How efficient is Exelixis business performance
The company's return on equity has surged by 132% QoQ and by 15% YoY
The ROA has soared by 127% from the previous quarter and by 8% YoY
The ROIC has soared by 110% from the previous quarter but it has contracted by 7% YoY
The company's return on sales has surged by 104% QoQ but it fell by 2.8% YoY

Dividends

What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXEL.

Financial health

How did Exelixis financials performed over time
EXEL's current ratio is down by 33% year-on-year and by 13% since the previous quarter
EXEL's quick ratio is down by 33% year-on-year and by 13% since the previous quarter
The debt is 92% less than the equity
The company's equity fell by 9% YoY and by 3.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.